Analytical method development and validation for the determination of Brinzolamide by RP-HPLC
Brinzolamide is inhibitor of carbonic anhydride and is highly specific and non-competitive. The aim of the present study is to develop a simple, precise, accurate, sensitive RP-HPLC method for the determination of bulk drug. The objective of the method validation is to demonstrate whether the method was suited for the intended purpose. The method was validated as per the ICH guidelines. The method was validated for linearity, precision (repeatability, intermediate precision), accuracy, specificity, robustness, ruggedness, limit of detection and limit of quantification. Cosmosil (4.6X250mm, 5 μ) column was used for separation. The selected wavelength for Brinzolamide was 254 nm. The mobile phase consists of Acetonitrile: Potassium dihydrogen phosphate buffer (40:60). Flow rate was delivered at 1.0 mL/min. Appropriate dilutions of standard stock solutions were prepared to get desired concentrations in the range of 100-500 mcg/ml. The equation od standard curve was y = 441.8x + 1132 and R2 = 0.998. The RT obtained was 6.6167 minutes.
Keywords: Brinzolamide, UV spectroscopy, RP-HPLC, ICH
(2) Agrawal, V. P.; Desai, S. S.; Jani, G. K. Development of Ultraviolet Spectrophotometric Method for the Simultaneous Estimation of Brimonidine Tartrate and Brinzolamide. Indian Drugs 2015, 52 (11), 29–34.
(3) Shah, P. A.; Kadikar, A. S.; Katira, R. M.; Patel, K. G.; Gandhi, T. R. Simultaneous Determination of Brinzolamide and Timolol Maleate Using Three Different Spectrophotometric Methods. World J. Pharm. Pharm. 2014, 3 (2), 1955–1967.
(4) Eissa, M. S.; Nour, I. M.; Elghobashy, M. R.; Shehata, M. A.; Chemistry department, A.; City, B.; El-, K. Validated Spectrophotometric Methods for Simultaneous Determination of Brinzolamide and Timolol Maleate in Their Pure Form and Ophthalmic Preparation. Al-Azhar J. Pharm. Sci. 2018, 54 (2), 188–202. https://doi.org/10.21608/ajps.2018.6643.
(5) Devi, C. M.; Kalita, P.; Dutta, R. S. Development and validation of simple UV spectrophotometric method for estimation of brinzolamide. J. Pharm. Sci. Innov. 2019, 8 (2), 60–63. https://doi.org/10.7897/2277-4572.02564.
(6) Vijya, P.; Patel, D.; Desai, S.; Meshram, D. Development and Validation of Derivative Spectrophotometric Method for Simultaneous Estimation of Brimonidine Tartrate and Brinzolamide in Combined Dosage Form. Indo Am. J. Pharm. Res. 2014, 4 (3), 1478.
(7) Anusha, B.; Geetha Susmita, A.; Rajitha, G. Analytical Method Development and Validation of New RP-HPLC Method for Simultaneous Estimation of Brinzolamide and Timolol Maleate in Ophthalmic Solutions. Res. J. Pharm. Biol. Chem. Sci. 2016, 7 (3), 1290–1298.
(8) Manoharan, G.; Al-Bratty, M. Development and Validation of Ultra Violet Spectrophotometric and Reversed-Phase High Performance Liquid Chromatography Techniques for Simultaneous Estimation of Brinzolamide and Brimonidine Tartrate in Ophthalmic Suspension Formulation. Orient. J. Chem. 2016, 32 (2), 1111–1120. https://doi.org/10.13005/ojc/320236.
(9) Agrawal, V. P.; Desai, S. S.; Jani, G. K. Development of RP-HPLC Method for Simultaneous Determination of Brimonidine Tartrate and Brinzolamide by QbD Approach and Its Validation. Eurasian J. Anal. Chem. 2016, 11 (2), 63–78. https://doi.org/10.12973/ejac.2016.122a.
(10) Kudumula, N.; Prasad Rajendra, Y. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Chlorthalidone and Cilnidipine in Bulk and Combined Tablet Dosage Form. Pharmacophore 2014, 5 (4), 442–450.
(11) Foivas, A.; Malenović, A.; Kostić, N. Quantitation of Brinzolamide in Dried Blood Spots by a Novel LC-QTOF-MS/MS Method. J. Pharm. Biomed. Anal. 2016, 119, 84–90.
(12) Mashru, R.; Senta, B. Development and Validation of Spectrophotometric Method for Simultaneous Estimation of Brinzolamide and Brimonidine Tartrate. Asian J. Pharm. Life Sci. 2014, 4 (2), 16–20.
(13) Khatun, R.; Islam, S. Development and Validation of Analytical Method for Simultaneous Estimation of Brinzolamide and Timolol by HPLC from Ophthalmic Preparation. Int. J. Pharm. Sci. Res. 2014, 5 (3), 1001–1007.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).